




COVID-19 agent molnupiravir

Molnupiravir (Lagevrio®) is an antiviral medication to treat mild to medium COVID-19 infection. Molnupiravir is actually a prodrug of the active substrate N⁴-hydroxycytidine (NHC), a synthetic ribonucleoside analogue. The treatment leads to the introduction of copying errors during viral RNA replication and by this inhibits the viral reproduction.

Molnupiravir and its active agent β-d-N⁴-hydroxycytidine can be separated by using a YMC-Triart C18 column and a MS compatible mobile phase at pH4.3 and relatively mild temperatures of 40°C.





Column: YMC Triart C18 (1.9 μ m, 12 nm) 50 x 2.1 mm ID
Part No.: TA12SP9-05Q1PT
Eluent: A) 10 mM HCOONH₄-HCOOH (pH 4.3)
B) 100 mM HCOONH₄-HCOOH (pH 4.3)/acetonitrile (10/90)
Gradient: 0-30 %B (0-0.6 min), 30 %B (0.6-2.6 min)
Flowrate: 0.4 mL/min
Temperature: 40°C
Detection: UV at 250 nm
Injection: 1 μ L (0.05 mg/mL, 0.1 mg/mL)